SPRUCE BIOSCIENCES, INC. (SPRB) Form 10-Q — May 13, 2026
Spruce Biosciences, Inc. reported a net loss of $12.3 million for the three months ended March 31, 2026, compared to a net loss of $14.0 million for the same period in 2025. The company's cash and cash equivalents as of March 31, 2026, were $54.1 million, up from $48.9 million at the end of 2025. The company has entered into a loan agreement with Avenue Capital Management II, L.P.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 6500
- Debt Amount
- 50000
- Revenue Yoy
- 0
- Total Assets
- 56166
- Cash Position
- 54080
- Deal Value Usd
- 0
- Interest Rate
- 12.25
- Maturity Date
- 2029-07-01
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 1372084
- Reverse split ratio
- 1:75
Price after filing
1 day: +2.5%7 days: -10.5%30 days: -14.7%
Close on the filing date to close N calendar days later (from $57.55). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.